Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2026)

Perspective Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $26.6 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $26.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $26.6 million in Q1 2026 per CATX's latest filing, from $26.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $26.6 million in Q1 2024 and troughed at $26.6 million in Q1 2024.
• A 3-year average of $26.6 million and a median of $26.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2025, down 0.0% in 2025.
• Over 3 years, Non-Current Deffered Revenue stood at $26.6 million in 2024, then changed by 0.0% to $26.6 million in 2025, then changed by 0.0% to $26.6 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $26.6 million, $26.6 million, and $26.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.